Emily Menendez

GU Oncology Now

Retroperitoneal lymph node dissection (RPLND) is an established treatment for patients with testicular germ cell tumors with minimal late morbidity. As the toxicities of chemotherapy and radiotherapy can negatively impact the quality of life of testicular cancer survivors, RPLND offers less burden to patients. However, little is known about the use and efficacy of RPLND in early metastatic seminoma.A prospective, phase 2, single-arm, multi-institutional trial led by Siamak Daneshmand, MD, aims to <a href="https://ascopubs.org/doi/abs/10.1200/JCO.22.00624" target="_blank" rel="noopener">examine the efficacy of surgery in early metastatic seminoma</a> by utilizing RPLND as a first-line treatment for testicular seminoma with clinically low-volume retroperitoneal lymphadenopathy.A total of 55 adult patients with testicular seminoma and isolated retroperitoneal lymphadenopathy (1-3 cm) were prospectively enrolled across 12 sites in the United States and Canada. Surgeons performed open RPLND on patients and assessed complication rates, recurrence patterns, pathologic up/downstaging, adjuvant therapies, and treatment-free survival.The median largest clinical lymph node size was 1.6 cm (range, 1.3-1.9 cm), while RPLND pathology reported a median largest lymph node size of 2.3 cm (range, 0.9-3.5 cm). One patient received adjuvant chemotherapy. A total of 9 patients (16%) were pN0, 12 (22%) were pN1, 31 (56%) were pN2, and 3 (5%) were pN3.The study&rsquo;s primary end point was 2-year recurrence-free survival (RFS). With a median follow-up of 33 months (range, 12.0-61.6 months), 12 patients experienced recurrence, with 10 patients undergoing chemotherapy and 2 receiving additional surgery. The 2-year RFS rate was 81%, and the recurrence rate was 22%.At the final follow-up, all patients who experienced recurrence were disease-free, and the 2-year overall survival rate was 100%. Short-term complications were noted in 4 patients (7%), and another 4 patients experienced long-term complications, including incisional hernia (1) and anejaculation (3).This prospective trial demonstrates the effectiveness of RPLND as a treatment option for testicular seminoma with clinically low-volume retroperitoneal lymphadenopathy that offers low long-term morbidity.

RPLND for Early Metastatic Seminoma Offers Low Long-term Morbidity

Testicular, Penile, and Rare Malignancies

A phase 2 trial aims to examine the efficacy of surgery in early metastatic seminoma by utilizing RPLND as a first-line treatment for testicular seminoma.

RPLND for Early Metastatic Seminoma Offers Low Morbidity

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe